# About Thymosin Alpha-1 Rx: An Independent Research Digest

> About Thymosin Alpha-1 Rx — an independent editorial project that summarizes the peer-reviewed Thymosin Alpha-1 literature. Not a clinic, not a vendor, no medical advice.

An independent editorial digest of the published Thymosin Alpha-1 record — and a clear account of what it is not.

## What this site is

Thymosin Alpha-1 Rx is an independent editorial project that publishes summaries of the peer-reviewed research literature on Thymosin Alpha-1 (thymalfasin). We read the published studies, summarize them in plain English, and cite every quantitative claim back to its source. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

## About the 'Rx' in the name

The 'Rx' in Thymosin Alpha-1 Rx is editorial framing, not a claim about services. It signals that the site reads the literature through the lens of how this peptide actually exists in the world — a drug (thymalfasin) approved and prescribed in roughly 35 countries, and not approved in the United States. The modifier describes a position the publisher occupies relative to the research, nothing more. There is no pharmacy here, no prescriber, no consultation, and no product. Nothing on this site can be ordered, dispensed, or filled.

## How we handle the evidence

We try to be precise where the data is precise and honest where it is not. That means surfacing the strong signal in chronic viral hepatitis and the well-documented benign safety profile, but also stating plainly that the largest, most rigorous sepsis trial was null, that much of the trial base is heterogeneous and often single-region, and that the molecule is constantly confused with other thymic peptides it is chemically distinct from. We never frame Thymosin Alpha-1 as anabolic, never assert unproven human benefit as fact, and never publish a human dose. Where the record carries a negative finding, we keep it next to the positive ones.

## Sources and corrections

Everything here is drawn from the peer-reviewed literature and public scientific record — PubMed-indexed studies, randomized controlled trials, and review articles — and every quantitative claim on the site is numbered and linked to its source on the references page. The human-experience material on the effects page is clearly separated from cited findings and labeled anecdotal, because reported impressions and measured outcomes are not the same kind of evidence and we will not let them blur. If you believe we have summarized a study incorrectly, missed a relevant trial, or let a claim drift past what its source supports, we want to know. The contact page is the way to reach the editorial desk, and we update the digest when a correction is warranted. This is a living summary of a moving field, not a fixed verdict.

---

A calm clinical-immunology reading room for the Thymosin Alpha-1 (thymalfasin) record — the dendritic-cell mechanism and the four decades of trials read straight, the strong hepatitis signal and the null sepsis result kept side by side, with no clinic behind the page and nothing here prescribed, dispensed, or sold.